Yarrow Bioscience Inc
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $97.0K | $86.0K | $69.0K | $202.0K | $84.0K | $121.0K | $198.0K | $98.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $788.0K | $817.0K | $4.9M | $6.1M | $9.7M | $10.2M | $7.3M | $3.7M |
| SG&A Expense | $2.4M | $3.1M | $2.7M | $3.3M | $3.2M | $3.0M | $3.3M | $3.8M |
| Operating Income | $-3.1M | $-3.8M | $-7.5M | $-9.2M | $-12.8M | $-13.1M | $-10.4M | $-7.4M |
| Operating Margin | -3,197.9% | -4,437.2% | -10,930.4% | -4,553.0% | -15,202.4% | -10,819.0% | -5,250.5% | -7,530.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-2.9M | $-3.6M | $-5.7M | $-8.6M | $-12.0M | $-12.2M | $-9.4M | $-6.2M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $4.0K | $0 | $0 | $0 |
| Net Income | $-3.0M | $-3.6M | $-5.8M | $-8.6M | $-12.0M | $-12.2M | $-9.4M | $-6.2M |
| Net Margin | -3,100.0% | -4,168.6% | -8,340.6% | -4,262.9% | -14,311.9% | -10,047.1% | -4,750.5% | -6,376.5% |
| EPS (Basic) | $-3.51 | $-0.08 | $-6.73 | $-0.20 | $-0.27 | $-0.02 | $-0.06 | $-0.04 |
| EPS (Diluted) | $-3.51 | $-0.08 | $-6.73 | $-0.20 | $-0.27 | $-0.02 | $-0.06 | $-0.04 |
| Shares Outstanding (Basic) | 858.0K | 42.8M | 855.0K | 42.7M | 42.6M | 511.0M | 170.3M | 170.3M |
| Shares Outstanding (Diluted) | 858.0K | 42.8M | 855.0K | 42.7M | 42.6M | 511.0M | 170.3M | 170.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |